Hence, our findings imply that HIF-1α downregulating PP2A activity and promoting tau phosphorylation might be a mechanism-based therapeutic target for treating chronic hypoxia-related cognitive deficits including in AD. The gene discussed is MAPT; the disease is Cognitive impairment.